Dermata Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
DRMA$0.77+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity
| Common Stock · Additional Paid-in · Accumulated · Total Stockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Par Value | Capital | Deficit | Equity | |
| Balance at December 31, 2024 | 251,725 | $25 | $67,236,408 | $(65,675,339) | $1,561,094 |
| Stock-based compensation | - | - | 37,189 | - | 37,189 |
| Issuance of Common Stock and warrants from January 2025 PIPE, net of issuance costs | 193,539 | 19 | 2,254,702 | - | 2,254,721 |
| Issuance of Common Stock upon exercise of pre-funded warrants | 97,746 | 10 | 967 | - | 977 |
| Issuance of Common Stock and warrants from March 2025 Warrant Inducement, net of issuance costs | 60,200 | 6 | 5,750,822 | - | 5,750,828 |
| Net loss | - | - | - | (2,303,587) | (2,303,587) |
| Balance at March 31, 2025 | 603,210 | $60 | $75,280,088 | $(67,978,926) | $7,301,222 |
| Stock-based compensation | - | - | 39,234 | - | 39,234 |
| Issuance of abeyance shares | 34,547 | 4 | (4) | - | - |
| Issuance costs related to the March 2025 Warrant Inducement | - | - | (25,112) | - | (25,112) |
| Net loss | - | - | - | (1,701,093) | (1,701,093) |
| Balance at June 30, 2025 | 637,757 | $64 | $75,294,206 | $(69,680,019) | $5,614,251 |
| Stock-based compensation | - | - | 37,840 | - | 37,840 |
| Issuance of abeyance shares | 206,700 | 20 | (20) | - | - |
| Net loss | - | - | - | (1,691,989) | (1,691,989) |
| Balance at September 30, 2025 | 844,457 | $84 | $75,332,026 | $(71,372,008) | $3,960,102 |
Statements of Stockholders’ Equity
| Common Stock · Additional Paid-in · Accumulated · Total Stockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Par Value | Capital | Deficit | Equity | |
| Balance at December 31, 2023 | 26,150 | $3 | $59,742,893 | $(53,387,878) | $6,355,018 |
| Stock-based compensation | - | - | 587,234 | - | 587,234 |
| Issuance of abeyance shares | 18,200 | 2 | (2) | - | - |
| Net loss | - | - | - | (3,134,262) | (3,134,262) |
| Balance at March 31, 2024 | 44,350 | $5 | $60,330,125 | $(56,522,140) | $3,807,990 |
| Stock-based compensation | - | - | 19,608 | - | 19,608 |
| Issuance of Common Stock upon exercise of warrants, net of issuance costs | 24,933 | 2 | 2,320,461 | - | 2,320,463 |
| Settlement of fractional shares paid in cash | (15) | - | (828) | - | (828) |
| Net loss | - | - | - | (2,829,106) | (2,829,106) |
| Balance at June 30, 2024 | 69,268 | $7 | $62,669,366 | $(59,351,246) | $3,318,127 |
| Stock-based compensation | - | - | 20,992 | - | 20,992 |
| Issuance of pre-funded warrants and warrants, net of issuance costs | - | - | 3,093,038 | - | 3,093,038 |
| Issuance of Common Stock upon exercise of pre-funded warrants | 16,756 | 2 | 166 | - | 168 |
| Issuance of Common Stock from ATM sales, net of issuance costs | 55,001 | 5 | 1,482,054 | - | 1,482,059 |
| Issuance of abeyance shares | 26,700 | 3 | (3) | - | - |
| Net loss | - | - | - | (3,173,156) | (3,173,156) |
| Balance at September 30, 2024 | 167,725 | $17 | $67,265,613 | $(62,524,402) | $4,741,228 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.